La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Can Fite Biofarma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Can Fite Biofarma..

Can Fite Biofarma (AMEX:CANF) Azioni, Catena delle Opzioni

CAN FITE BIOPHARMA LTD-ADR

Can Fite Biofarma

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd

Canfor Corp

CANFOR PULP PRODUCTS INC by Canfor Pulp Products, Inc.

Canfor Pulp Products Inc

Health Care

Press Releases

Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis

Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

Can-Fite Announces Up To $15.0 Million Public Offering

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Earnings

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson

CANF

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Alzamend Neuro

Aprea Therapeutics

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Entero Therapeutics

ESSA Pharma

Ernexa Therapeutics

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals

Genprex

HCW Biologics

IN8bio

Kala Bio

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

SILO Pharma

Silexion Therapeutics Corp - Ordinary Shares

Comments

Can Fite Biofarma

Can Fite Biofarma (CANF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO